Bhagat Mokshit, Kamal Raj, Sharma Jyoti, Kaur Kirandeep, Sharma Amit, Singh Thakur Gurjeet, Bhatia Rohit, Awasthi Ankit
Bachlor of Pharmacy, I.S.F College of Pharmacy, Moga, Punjab, India.
School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, 147301, India.
AAPS PharmSciTech. 2024 Dec 19;26(1):17. doi: 10.1208/s12249-024-03010-6.
Over the past years, many significant advances have been made in the field of gene therapy and shown promising results in clinical trials conducted. Gene therapy aims at modifying or replacing a defective, inefficient, or nonfunctional gene with a healthy, functional gene by administration of genome material into the cell to cure genetic diseases. Various methods have been devised to do this by using several viral and non-viral vectors which are either administered by in vivo or ex vivo technique. Viral vectors are best suitable for this therapy due to their potential to invade cells and deliver their genetic material whereas non-viral vectors are less efficient than viral vectors but possess some advantages such as less immunogenic response and large gene carrying capacity. Recent advances in biotechnology such as CRISPR-Cas9 mediated genome engineering and Cancer treatment with Chimeric antigen receptor (CAR) T-cell therapy are addressed in this review. This review article also delves into some recent research studies, gene therapy trials, and its applications, laying out future hopes for gene therapy in the treatment of various diseases namely haemophilia, Muscular dystrophy, SCID, Sickle cell disease, Familial Hypercholesterolemia, Cystic Fibrosis. Additionally, it also includes various nanoformulations and clinical trial data related to gene therapy.
在过去几年中,基因治疗领域取得了许多重大进展,并在进行的临床试验中显示出有前景的结果。基因治疗旨在通过将基因组物质导入细胞,用健康、有功能的基因修饰或替换有缺陷、效率低下或无功能的基因,以治愈遗传疾病。人们已经设计出各种方法来实现这一目标,即使用几种通过体内或体外技术施用的病毒和非病毒载体。病毒载体因其侵入细胞并传递其遗传物质的潜力而最适合这种治疗,而非病毒载体虽然比病毒载体效率低,但具有一些优点,如免疫原性反应较小和基因携带能力大。本文综述了生物技术的最新进展,如CRISPR-Cas9介导的基因组工程和嵌合抗原受体(CAR)T细胞疗法治疗癌症。这篇综述文章还深入探讨了一些近期的研究、基因治疗试验及其应用,阐述了基因治疗在治疗各种疾病(即血友病、肌肉萎缩症、重症联合免疫缺陷病、镰状细胞病、家族性高胆固醇血症、囊性纤维化)方面的未来希望。此外,它还包括与基因治疗相关的各种纳米制剂和临床试验数据。